KALV
Kalvista Pharmaceuticals Inc
NASDAQ: KALV · HEALTHCARE · BIOTECHNOLOGY
$26.66
+0.04% today
Updated 2026-05-04
Market cap
$1.42B
P/E ratio
—
P/S ratio
19.29x
EPS (TTM)
$-3.94
Dividend yield
—
52W range
$10 – $27
Volume
2.9M
Kalvista Pharmaceuticals Inc (KALV) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-223.20%
Operating margin
-21.20%
ROE
-190.20%
ROA
-61.00%
Debt/equity
8.80x
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2013 | $1.54M | $-2.05M | 100.00% | -119.18% | -133.49% |
| 2014 | $415000.00 | $-5.68M | 100.00% | -1,256.87% | -1,368.19% |
| 2014 | $29000.00 | $-13.36M | — | -40,265.52% | -46,065.52% |
| 2015 | $1.80M | $-7.23M | 99.54% | -448.39% | -400.55% |
| 2015 | $29000.00 | $-24.85M | 100.00% | -83,493.10% | -85,675.86% |
| 2016 | $7000.00 | $-6.61M | 100.00% | -93,257.14% | -94,385.71% |
| 2016 | $2.13M | $-11.44M | 99.31% | -711.72% | -536.15% |
| 2017 | $1.50M | $-18.60M | 99.16% | -1,485.31% | -1,236.90% |
| 2018 | $8.39M | $-15.80M | 99.78% | -222.84% | -188.29% |
| 2019 | $16.13M | $-20.82M | 99.78% | -184.91% | -129.08% |
| 2020 | $12.69M | $-29.12M | -216.74% | -319.41% | -229.44% |
| 2021 | $12.69M | $-46.24M | -325.34% | -456.45% | -364.41% |
| 2022 | $0.00 | $-82.34M | — | — | — |
| 2023 | $0.00 | $-92.91M | — | — | — |
| 2024 | $0.00 | $-126.64M | — | — | — |
| 2025 | $0.00 | $-183.44M | — | — | — |
| 2026 | $73.62M | $-164.29M | 91.75% | -233.42% | -223.16% |